Natera, Inc. (NASDAQ:NTRA) Insider Jonathan Sheena Sells 2,700 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Jonathan Sheena sold 2,700 shares of the firm’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $127.57, for a total transaction of $344,439.00. Following the transaction, the insider now directly owns 284,741 shares of the company’s stock, valued at approximately $36,324,409.37. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Jonathan Sheena also recently made the following trade(s):

• On Thursday, August 15th, Jonathan Sheena sold 12,000 shares of Natera stock. The shares were sold at an average price of $121.01, for a total value of $1,452,120.00.
• On Monday, August 12th, Jonathan Sheena sold 2,700 shares of Natera stock. The stock was sold at an average price of $113.82, for a total value of $307,314.00.
• On Monday, July 1st, Jonathan Sheena sold 2,700 shares of Natera stock. The shares were sold at an average price of $108.87, for a total value of $293,949.00.

Natera Stock Performance

NASDAQ NTRA opened at $127.78 on Friday. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. The stock’s 50 day simple moving average is $114.45 and its 200-day simple moving average is $105.31. The company has a market cap of $15.69 billion, a PE ratio of -40.96 and a beta of 1.53. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $132.01.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. During the same quarter last year, the firm posted ($0.97) EPS. The firm’s revenue for the quarter was up 58.1% on a year-over-year basis. As a group, equities research analysts anticipate that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Robert W. Baird upped their price objective on Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a research report on Wednesday, August 28th. Canaccord Genuity Group upped their price objective on shares of Natera from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Stephens restated an “overweight” rating and set a $125.00 target price on shares of Natera in a research report on Friday, August 9th. Finally, BTIG Research upped their price target on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, August 9th. One analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $120.07.

Hedge Funds Weigh In On Natera

Several hedge funds and other institutional investors have recently modified their holdings of NTRA. Principal Securities Inc. acquired a new stake in Natera in the 4th quarter valued at about $32,000. Envestnet Portfolio Solutions Inc. increased its holdings in shares of Natera by 16.4% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 7,590 shares of the medical research company’s stock valued at $475,000 after purchasing an additional 1,071 shares during the last quarter. Vanguard Personalized Indexing Management LLC lifted its position in Natera by 13.6% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 8,689 shares of the medical research company’s stock worth $544,000 after buying an additional 1,041 shares in the last quarter. Norges Bank purchased a new position in Natera during the fourth quarter worth approximately $83,970,000. Finally, Dynamic Technology Lab Private Ltd boosted its stake in Natera by 23.5% during the fourth quarter. Dynamic Technology Lab Private Ltd now owns 12,262 shares of the medical research company’s stock worth $768,000 after buying an additional 2,332 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.